[Clinical practice guideline for integrated PET/MRI in brain gliomas(2026 edition)].

To further standardize the clinical application of integrated PET/MRI brain imaging for brain gliomas in China, improve the level of precision diagnosis and management, promote standardized care, and provide evidence-based and consensus recommendations for imaging professionals and clinicians, this guideline was jointly developed by the Chinese Society of Medical Imaging Technology, Chinese Society of Radiology, Chinese Society of Nuclear Medicine, the Beijing Society of Nuclear Medicine, and the Beijing Society of Radiology, with the participation of multidisciplinary experts from nuclear medicine, radiology, neurosurgery, neuro-oncology, and radiation oncology, through multiple rounds of consensus meetings. Brain gliomas are among the most common primary brain tumors of the central nervous system, encompassing a wide spectrum of tumor grades and diverse biological behaviors. Key aspects of their clinical management include accurate diagnosis and grading, tumor extent delineation, preoperative evaluation and radiation therapy target planning, as well as differentiation between post-treatment recurrence and treatment-related changes. Integrated PET/MRI enables simultaneous acquisition of PET molecular metabolic information and multiparametric MRI structural and functional information within a single examination, effectively facilitating the above processes and serving as an important imaging modality for the precise diagnosis and treatment of brain gliomas. As integrated PET/MRI systems become increasingly available in China, broader clinical implementation continues to face challenges in appropriate indication selection, standardization of imaging workflows and parameter settings, image post-processing and assessment, consistency of image interpretation, and reporting. Grounded in the current accessibility of integrated PET/MRI equipment and tracers in China and in the latest domestic and international evidence-based research, and closely aligned with the realities of Chinese clinical practice, this guideline provides recommendations across key domains-clinical indications, examination and quality-control workflows, image interpretation, and standardized reporting-with the aim of offering systematic and practical evidence-based guidance for imaging specialists and clinicians involved in glioma care.